NMIBC — Intravesical Therapy Guide
Patient Testimonials

Patient Stories & Case Studies

Real treatment journeys from patients with high-grade non-muscle invasive bladder cancer. All cases are anonymized to protect patient privacy while sharing valuable experiences that may help others facing similar diagnoses.

Important Disclaimer

These case studies are for educational purposes only. Each patient's situation is unique, and treatment outcomes vary. The cases presented represent favourable outcomes and do not guarantee similar results. Always consult your urologist for personalized treatment recommendations.

5
Cases Shared
100%
Bladder Preserved
12–36
Months Disease-Free
4
Treatment Approaches

Case A68-year-old Male

36 months disease-free

Diagnosis

High-grade T1 papillary urothelial carcinoma with concurrent CIS, multifocal

Treatment

Bipolar en bloc resection (ESD) → Re-staging TURBT (negative) → BCG induction (6 weekly) → BCG maintenance (SWOG protocol, 3 years)

Outcome

Complete response at 3-month cystoscopy. Disease-free at 36-month follow-up with intact bladder.

Follow-up

Regular cystoscopy every 3 months for first 2 years, then every 6 months. Annual upper tract imaging. Currently on surveillance only.

I was terrified when I heard 'cancer', but the treatment was manageable. The en bloc resection was precise, and BCG kept my bladder safe. Three years later, I'm cancer-free and living normally.

— Patient A, 36 months post-treatment

Case B55-year-old Female

24 months disease-free

Diagnosis

High-grade Ta, recurrent after initial TURBT, BCG-relapsing (recurrence at 14 months after last BCG)

Treatment

Re-induction with BCG (6 weekly) → Maintenance BCG continued → Complete response achieved

Outcome

Complete response after re-induction. Remains disease-free at 24-month follow-up. Bladder preserved with good quality of life.

Follow-up

Cystoscopy with cytology every 3 months. No evidence of recurrence or progression. Continues maintenance BCG.

When the cancer came back, I thought I'd lose my bladder. But my doctor explained that late relapse responds well to more BCG. It worked! I'm grateful I didn't need surgery.

— Patient B, 24 months post-treatment

Case C72-year-old Male

18 months durable response

Diagnosis

BCG-unresponsive CIS (persistent CIS after adequate BCG: induction + maintenance × 2 courses)

Treatment

Patient declined cystectomy → Pembrolizumab (200 mg IV q3w) for 24 months

Outcome

Complete response at 3-month assessment (negative cystoscopy + cytology). Durable response maintained at 18-month follow-up.

Follow-up

Cystoscopy every 3 months during treatment. Manageable immune-related side effects (Grade 1 fatigue, mild rash). Quality of life maintained.

At 72, I wasn't ready for major surgery. Immunotherapy gave me another option. The infusions were easy, and my cancer responded. I still have my bladder and my independence.

— Patient C, 18 months post-treatment

Case D63-year-old Male

12 months disease-free

Diagnosis

High-grade T1 with CIS, BCG-unresponsive (recurrence within 6 months of adequate BCG)

Treatment

Patient declined cystectomy → Sequential Gemcitabine/Docetaxel (6 weekly inductions + monthly maintenance)

Outcome

Complete response at 3-month evaluation. Maintained response at 12-month follow-up with ongoing monthly maintenance instillations.

Follow-up

Cystoscopy every 3 months. Monthly intravesical maintenance well-tolerated. Minimal side effects (mild dysuria for 24 hours post-instillation).

The gemcitabine/docetaxel combination was surprisingly tolerable. Some burning for a day after each treatment, but nothing I couldn't handle. A year later, my scans are clear.

— Patient D, 12 months post-treatment

Case E58-year-old Female

18 months disease-free

Diagnosis

High-grade Ta, large (4 cm), multifocal. Initial presentation with gross haematuria.

Treatment

Complete bipolar en bloc resection (ESD) with blue light cystoscopy guidance → BCG induction (6 weekly) → BCG maintenance (SWOG, ongoing)

Outcome

Blue light cystoscopy detected 2 additional CIS lesions not visible under white light. All lesions completely resected en bloc. Disease-free at 18-month follow-up.

Follow-up

Cystoscopy every 3 months with cytology. BCG well-tolerated with only mild frequency/urgency for 48 hours post-instillation.

The blue light technology found hidden cancer spots that regular scopes would have missed. Combined with the en bloc technique, I felt confident everything was removed properly. The BCG side effects were mild — just some urgency that passed quickly.

— Patient E, 18 months post-treatment

Key Messages for Patients

Bladder Preservation is Possible

Many patients with high-grade NMIBC can keep their bladder with appropriate treatment. BCG and newer therapies offer effective alternatives to radical surgery.

BCG Failure ≠ End of Options

Even when BCG doesn't work, multiple effective treatments exist including immunotherapy, intravesical chemotherapy combinations, and novel FDA-approved agents.

Side Effects are Manageable

Most treatment side effects are temporary and mild. Your medical team can help manage symptoms to maintain your quality of life during treatment.

Regular Follow-up is Essential

Consistent surveillance with cystoscopy allows early detection of any recurrence, when it's most treatable. Adherence to follow-up schedules is key to long-term success.

If you or a loved one has been diagnosed with bladder cancer, consult a specialist urologist to discuss your treatment options.

Consult Dr. Chui Ka Lun